Karl Lewis, MD
Professor, Medicine-Medical Oncology

Photo
Medical School:
  • MD, Albany Medical College (1999)
Languages: English
Department: Medicine-Medical Oncology

Research Interests

My research interests focus on novel treatments for metastatic melanoma and I am currently the principal investigator or co-investigator on a number of therapeutic clinical trials.

Publications

  • Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res. 2020 Jan 1;26(1):46-53. doi: 10.1158/1078-0432.CCR-18-4180. PMID: 31732523
  • Ascierto PA, Lewis KD, Di Giacomo AM, Demidov L, Mandala M, Bondarenko I, Herberet C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko MJ, Goodman GR, Yan Y, Schadendorf D. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF V600 mutation-positive melanoma receiving adjuvant vemurafenib. Ann Oncol 2020 Jan;31(1):153-159. doi: 10.1016/j.annonc.2019.10.002. PMID: 31912791
  • Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fax BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tasa KK, Twitty C, Daud AI. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol 2020 Feb 1. doi: 10.1016/j.annonc.2019.12.008. PMID: 32147213
  • Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. PMID: 31952975
  • D’Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbe C, Lewis KD, Linette GP, Milella M, Georges S, Shah P, Ellers-Lenz B, Bajars M, Guzel G, Nghiem PT. Avelumab in patients with previously untreated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer 2020 May;8(1):e000674. doi: 10.1136/jitc-2020-000674. PMID: 23414862
  • Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALs, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, Squittieri N, Migden MR. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase 2 randonmised, double-blind BOLT study. Br J Dermatol. 2020 Jun;182(6):1369-1378. doi: 10.1111/bjd.18552. PMID: 31545507
  • Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire 150): primary analysis of the randomised, double-blind, pacebo-controlled, phase 3 trial. Lancet 2020 Jun 13;395(10240):1835-1844. doi: 10.1016/S0140-6736(20)30934-X. PMID: 32534646
  • Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, Tan AC, Robinson WA. Pre-treatment mutational and transcriptomic landscape of responding metastatic melanoma patients to anti-PD1 immunotherapy. Cancers. 2020 Jul 17;12(7):1943. doi 10.3390/cancers12071943. PMID: 32708981
  • Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dreno B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib +/- cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 Aug 3;18(1):294. doi: 10.1186/s12967-020-02458-x. PMID: 32746839
  • Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, Crowley E, Moscow J, Carter B, Patel S. A phase II study of glembatumumab vedotin for metastatic uveal melanoma. Cancers. 2020 Aug 13;12(8):E2270. doi: 10.3390/cancers12082270. PMID: 32823698
  • Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, Broit N, Amato CM, Van Gulick R, Kazakoff SH, Patch AM, Koufariotis LT, Lakis V, Leonard C, Wood S, Holmes O, Xu Q, Lewis K, Medina T, Gonzalez R, Saw RPM, Spillane AJ, Stretch JR, Rawson RV, Ferguson PM, Dodds TJ, Thompson JF, Long GV, Levesque MP, Robinson WA, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Hayward NK. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 Oct 16;11(1):5259. doi: 10.1038/s41467-020-18988-3. PMID: 33067454
  • Guidry J, Lewis K, Brown M. BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence. JAAD Case Rep. 2020 Jul 23;6(8):783-786. doi: 10.1016/j.jdcr.2019.07.023. PMID: 33015265; PMCID: PMC7525063.
  • Park SY, Church C, Alexander NA, Shinohara MM, Paulson KG, Lewis KD, Lee NS, Nghiem P. Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients. JAAD Case Rep. 2020 Dec 1;8:28-33. doi: 10.1016/j.jdcr.2020.11.020. PMID: 33490342; PMCID: PMC7806538.
  • McArthur GA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pareira R, Eigentler T, Rutkowski P, Demidov L, Moiseevich G, Yan Y, Huang KC, Uyei A, McNally V, Gutzmer R, Ascierto P. Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positiv advanced melanoma: Primary results from the phase 3 IMspire150 trial. American Association of Cancer Research (AACR) Annual Meeting. April, 2020.
  • Mansfield A, Hong D, Hann C, Farago A, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor M, Bryce AH, Tagawa S, Lewis K, Niu J, Chung C, Cleary J, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase 1/2 study of rovalpituzumab tesirine in delta-like 3-expressin, advanced solid tumors. American Society of Clinical Oncology (ASCO). June, 2020.
  • Lewis KD, Robert C, Ascierto PA, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler TK, Rutkowski P, Demidov LV, Moiseevich G, Tadesse-Bell S, Huang KC, McNally V, Mulla S, McArthur GA, Gutzmer R. Patient-reported outcomes (PROs) from the phase 3 IMspire 150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients with BRAFV600+ melanoma. American Society of Clinical Oncology (ASCO). June, 2020.
  • Slingluff CL, Blumenstein BA, Lewis KD, Andtbacka RHI, Hyngstrom R, Milhem MM, Markovic S, Hamid O, Hernandez-Aya LF, Bowles TL, Philips P, Jang S, Lutzky J, Bar A, Beitsch PD. Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma. American Society of Clinical Oncology (ASCO). June, 2020.
  • Sarnaik A, Khushalani NI, Chesney JA, Lewis KD, Medina TM, Kluger HM, Thomas SS, Musibay ED, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie PG, Lutzky J, Hamid O, Wu R, Shi W, Fardis M, Weber JS, Larkin J, Kirkwood JM. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. American Society of Clinical Oncology (ASCO). June, 2020.
  • Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Stankevich E, Booth J, Li S, Chen Z, Okoye E, Lowry I, Fury MG, Migden MR. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer follow up. American Society of Clinical Oncology (ASCO). June, 2020.
  • Ascierto PA, Robert C, Lewis KD, Munhoz R, Liszkay G, Merino L, Olah J, Queirolo P, Mackiewicz J, Li H, Zhu Q, McNally V, Mckenna EF, Gutzmer R, McArthur GA. Time to central nervous system (CNS) metastases with atezolizumab or placebo combined with cobimetinib + vemurafenib in the phase 3 IMspire 150 study. American Society of Clinical Oncology (ASCO). June, 2020.
  • Ho Felix, Torphy RJ, Tobin RP, Borges J, Vorwald VM, Amato CA, Van Gulick RV, Gonzalez R, Lewis KD, Medina TM, Rioth MJ, Gleisner AL, Robinson WA, McCarter MD. Immune checkpoint inhibitors in melanoma of unknown primary. Society of Surgical Oncology. August, 2020.
  • Stratigos AJ, Sekulic A, Peris K, Bechter O, Dutriaux C, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassuka I, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Sarda S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Primary analysis of phase 2 results for Cemiplimab in patients with locally acvanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). European Society of Medical Oncology (ESMO). September, 2020.
  • Ascierto PA, Robert C, Lewis K, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Elgentler T, Rutkowski P, Demidov L, Manikhas G, McNally V, Forbes H, Shah K, Yan Y, McArthur GA. Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 and/lactate dehydrogenase status: exploratory analyses from the IMspire150 study. European Society of Medical Oncology (ESMO). September, 2020.
  • Lewis K, Robert C, Ascierto PA, Munhoz R, Liszkay G, Merino L, Olah J, Queirolo P, Mackiewicz J, Li H, Zhu Q, McKenna E, McNally V, Gutzer R, McArthur GA. Incidence and time course of adverse events with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. European Society of Medical Oncology (ESMO). September, 2020.
  • Loquai C, Gutzmer R, Dummer R, Squittieri N, Lewis K, Migden M. 42-month results on the efficacy and safety of sonidegib in patients with aggressive and nonaggressive subtypes of locally advanced basal cell carcinoma. European Association of Dermato-Oncology (EADO). October, 2020.
  • Gutzmer R, Dummer R, Loauai C, Squittier N, Lewis K, Migden M. Effects of sonidegib dose reduction or delay in locally advanced basal cell carcinoma: 42-month data from BOLT. European Association of Dermato-Oncology (EADO). October, 2020.
  • Ascierto P, Lewis K, Robert C, Stroyakovskiy D, Gogas H, Prostenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas M, Li H, Zhu Q, McKenna E, McNally V, Gutzer R, McArthur G. Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire 150 study. Society for Immunotherapy of Cancer (SITC). November, 2020.
  • Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Hoch U, Currie SL, Nguyen T, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Progression-free survival and non-invasive correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. Society for Immunotherapy of Cancer (SITC). November, 2020.
  • Lewis K, Ascierto P, Robert C, Munhoz R, Liszkay G, Merino L, Olah J, Queirolo P, Mackiewicz J, Shah K, Forbes H, Hertig C, Yan Y, Gutzmer R, McArthur GA. Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with melanoma who have high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. Society for Immunotherapy of Cancer (SITC). November, 2020.
  • Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Li S, Yoo S, Mohan K, Coates E, Okoye E, Baurain J, Bechler O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves R, Ruiz ES, Seebach F, Weinreich DM, Yancopoulos GD, Lowry I, Bowler T, Fury MG. Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). Society for Immunotherapy of Cancer (SITC). November, 2020.
View All (30 Total) View Less

Professional Memberships

  • American Society of Clinical Oncology, Member
  • Southwest Oncology Group, Member
  • Society for Melanoma Research, Member

Practice Locations

University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

UCH - Cancer Center
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

Specialties
  • Internal Medicine, Board Certification
  • Medical Oncology, Board Certification (2004)
Conditions & Treatments
  • Cancers - Skin Cancer
  • Cancers - Melanoma
  • Cancers
Clinical Interests
My primary clinical interest is the treatment of malignant melanoma.

General Information

Medical Schools:
  • MD, Albany Medical College (1999)
Languages: English
Department: Medicine-Medical Oncology
;